Tryp Therapeutics: Unlocking the potential of psychedelics for chronic pain

Tryp Therapeutics: Unlocking the potential of psychedelics for chronic pain

ryp Therapeutics is a pharmaceutical company that is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications. In this video, Greg McKee, chairman and CEO, discusses Tryp’s clinical development programmes for fibromyalgia, phantom limb pain and other areas as well as the company’s rationale for using psilocybin for chronic pain.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free